The Biopatch antimicrobial dressing, from ETHICON (a Johnson & Johnson company), is supported by an evidence base of 14 randomised controlled trials for the prevention of Catheter Related Bloodstream Infections (CRBSIs) – delivering a decrease in the risk of these infections by up to 69%.
This innovative technology has been awarded a Category 1b recommendation from the Centres for Disease Control & Prevention (CDC) as well as Health Protection Scotland (HPS) and, most recently, was identified by the Department of Heath as 1 of 108 innovations that has the potential to make a real difference by transforming both quality and value across the NHS.
